Trial Profile
A Phase I study of daratumumab in combination with nivolumab in multiple myeloma.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2017
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 09 Jan 2017 New trial record